A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04662944
Status
Completed

Conditions

  • Neovascular Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
18 Years - 199 Years
Healthy Volunteers
Not accepted

Interventions

  • brolucizumab — DRUG
    There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
  • ranibizumab — DRUG
    There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
  • aflibercept — DRUG
    There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.

Study Details

RAZORBILL was an observational, multicenter, multinational, open-label, study designed primarily to investigate the influence of automated OCT image enrichment with segmentation information on disease activity assessment in nAMD patients treated with licensed anti-VEGFs

Key Dates

Start date
Feb 23, 2021
Status verified
Jun 2024
Primary completion
Jun 28, 2023
Completion
Jun 28, 2023

Study Design

Enrollment
494 participants (actual)

Arms

  • Arm: Licensed anti-VEGFs
    Patients being treated for nAMD with licensed anti-VEGFs

Primary Outcome Measure

Odds ratio of disease activity assessment from Optical Coherence Tomography (OCTs) with and without enrichment [ Time Frame: 12 months ]

Related Studies